Skip to main content

Leishmaniasis

4
Pipeline Programs
3
Companies
8
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
7 programs
1
1
allopurinolPhase 21 trial
GLA-SEPhase 11 trial
Clinical Investigation of Infections Due to Leishmanial ParasitesN/A1 trial
Diagnosis and Treatment of Leishmania InfectionsN/A1 trial
Expression of Mif Alleles in Individuals With LeishmaniasisN/A1 trial
+2 more programs
Active Trials
NCT00001169Completed250Est. Feb 2001
NCT00344188Recruiting289
NCT00401349Completed438Est. Apr 2010
+4 more trials
ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
2
GSK3186899Phase 1
GSK3494245Phase 1
Knight Therapeutics
Knight TherapeuticsQC - Montréal
1 program
MiltefosineN/A1 trial
Active Trials
NCT02429505Withdrawn0Est. Mar 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Allergy Therapeuticsallopurinol
Allergy TherapeuticsGLA-SE
Knight TherapeuticsMiltefosine
Allergy TherapeuticsTh1/Th2 Polarization and Linkage to L. Viannia Infection Outcomes
Allergy TherapeuticsExpression of Mif Alleles in Individuals With Leishmaniasis
Allergy TherapeuticsDiagnosis and Treatment of Leishmania Infections
Allergy TherapeuticsClinical Investigation of Infections Due to Leishmanial Parasites

Clinical Trials (8)

Total enrollment: 1,522 patients across 8 trials

NCT00004755Allergy Therapeuticsallopurinol

Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil

Start: Sep 1995375 patients
Phase 2Completed
NCT01437020Allergy TherapeuticsSCH708980 Anti-IL-10 monoclonal

SCH708980 With and Without AmBisome for Visceral Leishmaniasis

0
Phase 1/2Withdrawn
NCT01751048Allergy TherapeuticsGLA-SE

LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine

Start: Mar 2013Est. completion: Jan 201548 patients
Phase 1Completed
NCT02429505Knight TherapeuticsMiltefosine

Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry

Start: Jul 2015Est. completion: Mar 20200
N/AWithdrawn
NCT00401297Allergy TherapeuticsTh1/Th2 Polarization and Linkage to L. Viannia Infection Outcomes

Th1/Th2 Polarization and Linkage to L. Viannia Infection Outcomes

Start: Dec 2006Est. completion: Apr 2010122 patients
N/ACompleted
NCT00401349Allergy TherapeuticsExpression of Mif Alleles in Individuals With Leishmaniasis

Expression of Mif Alleles in Individuals With Leishmaniasis

Start: Dec 2006Est. completion: Apr 2010438 patients
N/ACompleted
NCT00344188Allergy TherapeuticsDiagnosis and Treatment of Leishmania Infections

Diagnosis and Treatment of Leishmania Infections

Start: Nov 2001289 patients
N/ARecruiting
NCT00001169Allergy TherapeuticsClinical Investigation of Infections Due to Leishmanial Parasites

Clinical Investigation of Infections Due to Leishmanial Parasites

Start: Dec 1979Est. completion: Feb 2001250 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,522 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.